Predict your next investment

AxImmune company logo
HEALTHCARE | Biotechnology
aximmune.com

See what CB Insights has to offer

Stage

Grant | Alive

Total Raised

$250K

Last Raised

$250K | 3 yrs ago

About AxImmune

AxImmune is developing clinical stage immuno-oncology (IO) technology in-licensed from Colorado State University (CSU) and other parties.

AxImmune Headquarter Location

12635 E Montview Blvd Suite 100G

Aurora, Colorado, 80045,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AxImmune

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AxImmune is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

AxImmune Patents

AxImmune has filed 1 patent.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/3/2017

Immunology, Monoclonal antibodies, Experimental cancer drugs, Immune system, Monoclonal antibodies for tumors

Application

Application Date

11/3/2017

Grant Date

Title

Related Topics

Immunology, Monoclonal antibodies, Experimental cancer drugs, Immune system, Monoclonal antibodies for tumors

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.